High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

NCT ID: NCT06418789

Last Updated: 2025-08-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-01
• Study Completion Date: 2029-03-01

Brief Summary

This is a prospective, single-center, non-randomized phase II study. Patients with germ cell tumors of gonadal and extragonadal localization who have progressed after prior platinum-containing first-line chemotherapy will receive high-dose chemotherapy with TI (2 cycles) folollowed by high dose CE chemotherapy with autologous stem cell transplantation (3 cycles). The primary endpoint of the study is to evaluate the efficacy high-dose chemotherapy as second-line drug therapy for patients with advanced germ cell tumors.

Detailed Description

Germ cell tumors are curable diseases. Only a small proportion of patients fail to be cured: those who experience a primary resistance to chemotherapy and those who relapsed after first line conventional dose cisplatin-based chemotherapy. Nowadays, there is heterogeneity of practice in salvage approaches. This includes conventional chemotherapy high dose chemotherapy with autologous stem cell transplant. Best choice of the therapy strategy is an unmet clinical need now. This is why this single-center, non-randomized phase II study will be conducted at the N.N. Petrov National Medical Research Center of Oncology. Patients with germ cell tumors of gonadal and extragonadal localization who have progressed after prior platinum-containing first-line chemotherapy will receive two cycles of high-dose TI (Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest; leukapheresis will be performed starting on day 11 in case of CD45+CD34+ blood level above 20x10^6/L is achieved), followed by three cycles of high dose CE (Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m^2 IV daily days -4 to -2, autlologous stem cell transplantation at day 0, GCSF support from day 4.) The primary endpoint of the study is to evaluate the efficacy by measuring progression-free survival. The secondary endpoints of the trial are overall survival, response rate by RECIST, safety and prognostic factors analysis.

Conditions

Germ Cell Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group 1

In arm patients receive a TI-CE regime based on paclitaxel and ifosfamide in cycles 1-2 and carboplatin and etoposide in cycles 3-5.

Group Type: EXPERIMENTAL

High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )

Intervention Type: DRUG

TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10^6/L is achieved.

CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m^2 IV daily days -4 to -2, autlologous stemm cell transplantation >=2*10^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1*10^9/L.

Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6*10^6 CD34+ stem cells will be harvested.

Interventions

High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )

TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10^6/L is achieved.

CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m^2 IV daily days -4 to -2, autlologous stemm cell transplantation >=2*10^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1*10^9/L.

Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6*10^6 CD34+ stem cells will be harvested.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patient is able to provide informed consent and sign approved consent forms to participate in the study.

2. Males ≥ 18 years of age at the time of signing the IC Form.

3. Histologically verified diagnosis of GO (seminomatous, non-seminomatous).

2. Any (gonadal and extragonadal (retroperitoneal, mediastinal, etc.)) localization of primary GO.

3. Progression after 3 or 4 cycles of platinum-containing first-line chemotherapy (ВЕР or EP).

4. Required Initial Laboratory Values:

• Hemoglobin ≥ 90 g/L;
• neutrophils ≥ 1.5 x 109/L;
• platelets ≥ 75 x 109/L;
• creatinine ≥ 1.5 x HGH (or CKF ≤ 60 mL/min);
• ALT or AST ≥ 2.5 x HGN (5 x HGN for patients with liver metastases);
• bilirubin ≥ 1.5 x IUH (except for patients with Gilbert syndrome, in whom total bilirubin levels should not exceed 50 μmol/L);
• alkaline phosphatase ≥ 2.5 x IUH. 5. Absence of neurologic symptoms in the presence of CNS metastases (asymptomatic CNS metastases are acceptable).

Exclusion Criteria

1. Primary CS of the brain

2. Administration of ≥2 lines of prior drug therapy for disseminated GO.

3. Presence of active hepatitis B or hepatitis C, HIV infection, acute infectious disease, or activation of chronic infectious disease less than 28 days prior to study inclusion.

4. Conditions that limit the patient's ability to fulfill the requirements of the protocol (psychiatric disorders, drug or alcohol dependence).

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

N.N. Petrov National Medical Research Center of Oncology

OTHER

Sponsor Role: lead

Responsible Party

Anna Igorevna Semenova

clinical oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Aleksei M Belyaev, MD,DSc,Prof.

Role: STUDY_DIRECTOR

National Medical Research Center of Oncology named after N.N.Petrov Ministry of health of Russia

Tatyana Yu Semiglazova, MD,DSc,Prof.

Role: STUDY_CHAIR

National Medical Research Center of Oncology named after N.N.Petrov Ministry of health of Russia

Locations

National Medical Research Center of Oncology named after N.N.Petrov Ministry of health of Russia

Saint Petersburg, Russian Federation, Russia

Site Status: RECRUITING

Countries

Russia

Central Contacts

Anna Semenova, MD, PhD

Role: CONTACT

mirannia@yandex.ru

8 (812) 439-95-05

Facility Contacts

Anna I Semenova, MD, PhD

Role: primary

Other Identifiers

German2

Identifier Type: -

Identifier Source: org_study_id